WAIKOLOA, Hawaii — Sunitinib, a novel intravitreal anti-VEGF delivered via a biodegradable depot for extended treatment of neovascular age-related macular degeneration, met its primary endpoint of safety and tolerability, a speaker here said.
David Boyer, MD, delivered the 6-month phase 1/2a study results for GB-102 (Graybug Vision) at Retina 2019.
“There is a clear and durable pharmacodynamic effect of GB-102 based on the analysis of both best corrected vision and OCTs,” Boyer said. Thirty-two subjects with diagnosed neovascular AMD for less than 18 months were enrolled. All